Phase 2b program with sonlicromanol in patients with mitochondrial disease due to m.3243A>G mutation
Brain · 2025
DOI: 10.1093/brain/awae277 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Brain, 2025. Verfasst von Jan Smeitink und 19 weiteren Autor:innen. Beteiligte Einrichtung: Khondrion B.V., 6534 AT Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Mitochondrial Diseases, DNA, Mitochondrial. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Khondrion B.V., European Innovation Council Horizon Europe, Energy4all.
Abstract (Originalsprache)
Mitochondrial disease incorporates a group of rare conditions with no approved treatment to date, except for Leber hereditary optic neuropathy. Therapeutic options to alleviate the symptoms of mitochondrial disease are urgently needed. Sonlicromanol is a promising candidate, as it positively alters the key metabolic and inflammatory pathways associated with mitochondrial disease. Sonlicromanol is a reductive and oxidative distress modulator, selectively inhibiting microsomal prostaglandin E1 synthase activity. This phase 2b program, aimed at evaluating sonlicromanol in adults with m.3243A>G mutation and primary mitochondrial disease, consisted of a randomized controlled (RCT) study (dose-selection) followed by a 52-week open-label extension study (EXT, long-term tolerability, safety and efficacy of sonlicromanol). Patients were randomized (1:1:1) to receive 100 or 50 mg sonlicromanol or placebo twice daily (bid) for 28 days with a ≥2-week wash-out period between treatments. Patients who completed the RCT study entered the EXT study, wherein they received 100 mg sonlicromanol bid. Overall, 27 patients were randomized (24 RCT patients completed all periods). Fifteen patients entered the EXT, and 12 patients were included in the EXT analysis set. All patients reported good tolerability and favourable safety, with pharmacokinetic results comparable to the earlier phase 2a study. The RCT primary end point [change from placebo in the attentional domain of the cognition score (visual identification; Cogstate IDN)] did not reach statistical significance. Using a categorization of the subject's period baseline a treatment effect over placebo was observed if their baseline was more affected (P = 0.0338). Using this approach, there were signals of improvements over placebo in at least one dose in the Beck Depression Inventory (BDI, P = 0.0143), Cognitive Failure Questionnaire (P = 0.0113) and the depression subscale of the Hospital Anxiety and Depression Scale (P = 0.0256). Statistically and/or clinically meaningful improvements were observed in the patient- and clinician-reported outcome measures at the end of the EXT study [Test of Attentional Performance (TAP) with alarm, P = 0.0102; TAP without alarm, P = 0.0047; BDI somatic, P = 0.0261; BDI total, P = 0.0563; SF12 physical component score, P = 0.0008]. Seven of nine domains of RAND-Short Form-36-like SF-36 pain improved (P = 0.0105). Other promising results were observed in the Neuro-Quality of Life Short Form-Fatigue Scale (P = 0.0036), mini-Balance Evaluation Systems test (P = 0.0009), McGill Pain Questionnaire (P = 0.0105), EuroQol EQ-5D-5L-Visual Analog Scale (P = 0.0213) and EQ-5D-5L-Index (P = 0.0173). Most patients showed improvement in the Five Times Sit-To-Stand Test. Sonlicromanol was well-tolerated and demonstrated a favourable benefit/risk ratio for up to 1 year. Sonlicromanol was efficacious in patients when affected at baseline, as seen across a variety of clinically relevant domains. Long-term treatment showed more pronounced changes from baseline.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Khondrion B.V., 6534 AT Nijmegen, The Netherlands.
- Certara Netherlands B.V., 5349 AB Oss, The Netherlands.
- Department of Internal Medicine, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
- Department of Neurology, Friedrich-Baur-Institute, LMU University Hospital, Ludwig-Maximilians-Universität München, 80336 Munich, Germany.
- German Center for Neurodegenerative Diseases (DZNE), 81377 Munich, Germany.
- Munich Cluster for Systems Neurology, 81377 Munich, Germany.
Förderung
- Khondrion B.V.
- European Innovation Council Horizon Europe
- Energy4all
- Join4Energy
- Ride4Kids
- Tim Foundation
- Road4Energy
Zitieren
APA
Smeitink, J., van Es, J., Bosman, B., Janssen, M. C. H., Klopstock, T., Gorman, G., Vissing, J., Ruiterkamp, G., Edgar, C. J., Abbink, E. J., van Maanen, R., Pogoryelova, O., Stendel, C., Bischoff, A., Karin, I., Munshi, M., Kümmel, A., Burgert, L., Verhaak, C., & Renkema, H. (2025). Phase 2b program with sonlicromanol in patients with mitochondrial disease due to m.3243A>G mutation. Brain. https://doi.org/10.1093/brain/awae277
Vancouver
Smeitink J, van Es J, Bosman B, Janssen MCH, Klopstock T, Gorman G, et al. Phase 2b program with sonlicromanol in patients with mitochondrial disease due to m.3243A>G mutation. Brain. 2025. doi:10.1093/brain/awae277
BibTeX
@article{Smeitink2025,
author = {Smeitink, Jan and van Es, Just and Bosman, Brigitte and Janssen, Mirian C H and Klopstock, Thomas and Gorman, Grainne and Vissing, John and Ruiterkamp, Gerrit and Edgar, Chris J and Abbink, Evertine J and van Maanen, Rob and Pogoryelova, Oksana and Stendel, Claudia and Bischoff, Almut and Karin, Ivan and Munshi, Mahtab and Kümmel, Anne and Burgert, Lydia and Verhaak, Christianne and Renkema, Herma},
title = {Phase 2b program with sonlicromanol in patients with mitochondrial disease due to m.3243A>G mutation},
journal = {Brain},
year = {2025},
doi = {10.1093/brain/awae277}
}
EUVIMED